Literature DB >> 29621548

TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease.

Youwen Zhang1, Shujun Feng2, Kun Nie2, Yan Li2, Yuyuan Gao2, Rong Gan2, Limin Wang2, Bing Li2, Xuegang Sun3, Lijuan Wang4, Yuhu Zhang5.   

Abstract

Neuroinflammation and overactivated microglia underlies the pathogenesis of Parkinson's disease (PD). Furthermore, microglia could polarize into classic inflammatory M1 and immunosuppressive M2 phenotype. Thus, inhibiting the overactivated inflammatory M1 microglia by promoting the transformation of microglia to the protective M2 phenotype provides potential therapy for PD, but the mechanism that modulates microglia polarization remains unknown. Triggering receptor expressed on myeloid cells-2 (TREM2) is a recently identified immune receptor expressed by the microglia in the brain. Emerging evidence indicates that TREM2 enhances the phagocytosis function of microglia and suppress inflammation. Based on these evidence, we hypothesized that TREM2 might play a protective role through regulating microglia polarization. Here, we employ a lentiviral strategy to overexpress or suppress TREM2 on microglia and found that TREM2 was essential for M2 microglia polarization. Knockdown of TREM2 in BV2 microglia inhibited M2 polarization and lead to exaggeration of M1 microglial inflammatory responses, whereas overexpression of TREM2 promoted M2 polarization and alleviated microglial inflammation. We also observed that the TREM2 level was higher in the midbrain of PD mice, which was accompanied by an elevated level of Arginase-1 and increased proinflammatory cytokines, suggesting that TREM2 is an important factor in switching the microglia phenotypes. Taken together, these findings indicate that TREM2 plays a crucial role in altering the proinflammatory M1 microglia to M2 phenotype and has beneficial effects in the immune pathogenesis of PD.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Microglia; Neuroinflammation; Parkinson's disease; Polarization; Triggering receptor expressed on myeloid cells 2

Mesh:

Substances:

Year:  2018        PMID: 29621548     DOI: 10.1016/j.bbrc.2018.03.226

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  35 in total

1.  Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.

Authors:  Jerel Adam Fields; Brian Spencer; Mary Swinton; Emma Martine Qvale; María J Marquine; Arina Alexeeva; Sarah Gough; Benchawanna Soontornniyomkij; Elvira Valera; Eliezer Masliah; Cristian L Achim; Paula Desplats
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

2.  Pretreatment with crocin along with treadmill exercise ameliorates motor and memory deficits in hemiparkinsonian rats by anti-inflammatory and antioxidant mechanisms.

Authors:  Somayeh Shahidani; Ziba Rajaei; Hojjatallah Alaei
Journal:  Metab Brain Dis       Date:  2019-01-16       Impact factor: 3.584

Review 3.  Microglia Phenotypes in Aging and Neurodegenerative Diseases.

Authors:  Menbere Y Wendimu; Shelley B Hooks
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

Review 4.  Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Authors:  Maamoon Saleh; Milica Markovic; Katherine E Olson; Howard E Gendelman; R Lee Mosley
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  Extracellular Hsp90α stimulates a unique innate gene profile in microglial cells with simultaneous activation of Nrf2 and protection from oxidative stress.

Authors:  Yuka Okusha; Benjamin J Lang; Ayesha Murshid; Thiago J Borges; Kristina M Holton; Joanne Clark-Matott; Sachin Doshi; Tsuneya Ikezu; Stuart K Calderwood
Journal:  Cell Stress Chaperones       Date:  2022-06-10       Impact factor: 3.827

6.  Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.

Authors:  Caroline Diorio; Rawan Shraim; Regina Myers; Edward M Behrens; Scott Canna; Hamid Bassiri; Richard Aplenc; Chakkapong Burudpakdee; Fang Chen; Amanda M DiNofia; Saar Gill; Vanessa Gonzalez; Michele P Lambert; Allison Barz Leahy; Bruce L Levine; Robert B Lindell; Shannon L Maude; J Joseph Melenhorst; Haley Newman; Jessica Perazzelli; Alix E Seif; Simon F Lacey; Carl H June; David M Barrett; Stephan A Grupp; David T Teachey
Journal:  Clin Cancer Res       Date:  2022-09-01       Impact factor: 13.801

7.  TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models.

Authors:  Ying Guo; Xinbing Wei; Hua Yan; Yue Qin; Shaoqi Yan; Jia Liu; Yong Zhao; Fan Jiang; Haiyan Lou
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

Review 8.  The role of efferocytosis in neuro-degenerative diseases.

Authors:  Forough Taheri; Eskandar Taghizadeh; Jamshid Gholizadeh Navashenaq; Mehdi Rezaee; Seyed Mohammad Gheibihayat
Journal:  Neurol Sci       Date:  2022-01-21       Impact factor: 3.307

9.  Metformin Therapy Attenuates Pro-inflammatory Microglia by Inhibiting NF-κB in Cuprizone Demyelinating Mouse Model of Multiple Sclerosis.

Authors:  Mahdad Abdi; Parichehr Pasbakhsh; Maryam Shabani; Saied Nekoonam; Asie Sadeghi; Fardin Fathi; Morteza Abouzaripour; Wael Mohamed; Kazem Zibara; Iraj Ragerdi Kashani; Adib Zendedel
Journal:  Neurotox Res       Date:  2021-09-27       Impact factor: 3.911

10.  Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction.

Authors:  Ayan Hussein; Christopher A Guevara; Pamela Del Valle; Swati Gupta; Deanna L Benson; George W Huntley
Journal:  Neuroscientist       Date:  2021-05-08       Impact factor: 7.235

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.